Former My-K Labs president Kun Chae Bae is requesting a hearing on FDA's March 30 proposal to permanently debar him from participating in the drug approval process. Bae was sentenced in December 1990 to three months work release and a $25,000 fine for making illegal payments totaling $30,000 to former FDA generic drugs branch chief Charles Chang and for giving gifts to a buyer for a Defense Personnel Support Center. Former Vitarine VP for manufacturing John Bushlow is asking for a hearing on FDA's Feb. 5 proposal to permanently debar him. Bushlow was sentenced in February 1992 to four months in jail for failing to establish and keep drug manufacturing records with intent to mislead.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth